


Accepted Manuscript

Current insights into the German Lipoproteinapheresis Standard: PCSK9-Inhibitors, Lipoprotein Apheresis or both?

V.J.J. Schettler, J. Ringel, S. Jacob, U. Julius, R. Klingel, F. Heigl, E. Roeseler, P. Grützmacher



PII: S1567-5688(17)30047-8

DOI: [10.1016/j.atherosclerosissup.2017.05.005](https://doi.org/10.1016/j.atherosclerosissup.2017.05.005)

Reference: ATHSUP 297

To appear in: *Atherosclerosis (Supplements) (Component)*

Please cite this article as: Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, for the German Society of Nephrology (DGfN), for the Foundation of German Centers of Nephrology (DN), Current insights into the German Lipoproteinapheresis Standard: PCSK9-Inhibitors, Lipoprotein Apheresis or both?, *Atherosclerosis (Supplements) (Component)* (2017), doi: 10.1016/j.atherosclerosissup.2017.05.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Current insights into the German Lipoproteinapheresis Standard: PCSK9-Inhibitors, Lipoprotein Apheresis or both?

V.J.J. Schettler¹, J. Ringel², S. Jacob³, U. Julius⁴, R. Klingel⁵, F. Heigl⁶, E. Roeseler⁷, P. Grützmacher⁸ for the German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN)

¹Center of Nephrology Göttingen GbR, Göttingen, Germany

²Center for Dialysis Potsdam, Potsdam, Germany

³Medical Center for Prevention and Therapy, Villingen-Schwenningen, Germany

⁴Department of Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany

⁵Apheresis Research Institute, Cologne, Germany; 1st Department of Internal Medicine, University of Mainz, Mainz, Germany

⁶Medical Care Centre Kempten-Allgäu, Kempten, Germany

⁷Center for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany

⁸Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany

Corresponding author:

Priv. Doz. Dr. med. Volker Schettler, Center of Nephrology Göttingen GbR

An der Lutter 24, 37075 Göttingen, Germany

Tel.: 0551-30985312, Fax: 0551-30985355, E-Mail: v.schettler@nz-goe.de

Key words: Lipoprotein apheresis, PCSK9-inhibitor, LDL-Cholesterol, Lipoprotein(a), cardiovascular events, guideline.

Conflict of interest/ Disclosures: V.J.J. Schettler received honoraria from Fresenius Medical Care, Diamed, Kaneka, AMGEN and SANOFI-Aventis. J. Ringel received honoraria from Fresenius Medical Care, Diamed, Kaneka, AMGEN, MSD, BerlinChemie and SANOFI-Aventis. U. Julius: travel expenses by Aegerion, Diamed, Fresenius Medical Care, Kaneka; honoraria from Aegerion, Amgen, Chiesi, Sanofi, Kaneka, Diamed, Fresenius Medical Care. R. Klingel received research grants from Asahi Kasei Medical, Japan and Diamed, Germany. P. Grützmacher received honoraria from Amgen, Braun, Fresenius Medical Care, MSD, Sanofi-Aventis. All other authors had none declared. The other authors report no conflicts.

Download English Version:

<https://daneshyari.com/en/article/8657252>

Download Persian Version:

<https://daneshyari.com/article/8657252>

[Daneshyari.com](https://daneshyari.com)